Eli Lilly and Company (NYSE:LLY) Shares Bought by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 3.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,723 shares of the company’s stock after acquiring an additional 276 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Eli Lilly and Company were worth $7,898,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth about $6,916,000. M&G Plc purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth about $8,896,000. IPG Investment Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $351,000. Finally, HighPoint Advisor Group LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $9,878,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on LLY shares. Barclays boosted their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Berenberg Bank boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the transaction, the insider now directly owns 97,367,369 shares in the company, valued at $89,093,089,982.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 442,229 shares of company stock worth $410,002,456. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Up 0.7 %

NYSE LLY opened at $921.72 on Friday. The company has a market capitalization of $876.01 billion, a price-to-earnings ratio of 135.75, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The company’s fifty day moving average price is $895.06 and its two-hundred day moving average price is $837.89.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were issued a $1.30 dividend. The ex-dividend date was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.